This just about sums it up dejavu I think Leron
Post# of 148184
Quote:
I think Leronlimab will still have plenty of a role for CV, as it's likely to be the first with real data and real efficacy to hit the market, manufacturing capacity will be able to meet demand, Leronlimab handling and transportation and administration of a subcutaneous injection is vastly simpler than most treatments (stem cells, IV, RNA vaccines, etc)
I'll only add one more important factor... Leronlimab has very little, if any, negative side effects and seemingly a quicker positive reaction... remember what Dr. Lalezari said a couple of days ago:
Quote:
Most patients are showing great improvement by day three... surprising how quickly getting much better
Read More: https://investorshangout.com/post/view?id=576...z6MYDHIvzL